Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 9/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.80 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.80 |
| ▸ | MEN1 | O00255 | 2/20 | 0.80 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.80 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.80 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.80 |
| ▸ | GLA | P06280 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.80 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | GABRP | O00591 | 1/20 | 0.55 |
| ▸ | GABRD | O14764 | 1/20 | 0.55 |
| ▸ | GMNN | O75496 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alfadolone SCHEMBL2512102 | 1.00 | G6PD (1.00) | G6PDGABRA1GABRB2CYP3A4CYP2C9 | |
| Alfadolone SCHEMBL14525649 | 1.00 | G6PD (1.00) | G6PDGABRA1GABRB2CYP3A4CYP2C9 | |
| Alfadolone SCHEMBL30555809 | 1.00 | G6PD (1.00) | G6PDGABRA1GABRB2CYP3A4CYP2C9 | |
| Alfadolone SCHEMBL17223283 | 1.00 | G6PD (1.00) | G6PDGABRA1GABRB2CYP3A4CYP2C9 | |
| Alfadolone SCHEMBL2512103 | 1.00 | G6PD (1.00) | G6PDGABRA1GABRB2CYP3A4CYP2C9 | |
| Alfadolone SCHEMBL20075616 | 1.00 | G6PD (1.00) | G6PDGABRA1GABRB2CYP3A4CYP2C9 | |
| Alfadolone SCHEMBL24023700 | 1.00 | G6PD (1.00) | G6PDGABRA1GABRB2CYP3A4CYP2C9 | |
| Alfadolone SCHEMBL28333104 | 1.00 | G6PD (1.00) | G6PDGABRA1GABRB2CYP3A4CYP2C9 | |
| Alfadolone SCHEMBL21614058 | 1.00 | G6PD (1.00) | G6PDGABRA1GABRB2CYP3A4CYP2C9 | |
| Alfadolone SCHEMBL750779 | 1.00 | G6PD (1.00) | G6PDGABRA1GABRB2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 356 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2916846-B1 | NEUROACTIVE STEROIDS AND THEIR USE TO FACILITATE NEUROPROTECTION | DRAWBRIDGE PHARMACEUTICALS PTY LTD (AU) | 2025-09-17 | — | — | EP | claimed |
| CN-119174771-A | Neuroactive steroid self-microemulsifying composition and preparation method and application thereof | 北京华睿鼎信科技有限公司 | 2024-12-24 | — | — | CN | claimed |
| CN-118873539-A | Neuroactive steroid solid dispersion, solid dispersion composition, preparation method and application thereof, and medicine containing solid dispersion | 北京华睿鼎信科技有限公司 | 2024-11-01 | — | — | CN | claimed |
| CN-116267014-A | Cyclic deuterated gaboxadol and its use for treating psychotic disorders | CERTEGO治疗公司 | 2023-06-20 | — | — | CN | claimed |
| US-20230183238-A1 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | CERTEGO ABC, LLC | 2023-06-15 | — | — | US | claimed |
| EP-4153549-A2 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | Certego Therapeutics Inc. (US) | 2023-03-29 | — | — | EP | claimed |
| US-11597726-B2 | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders | Certego Therapeutics Inc. (US) | 2023-03-07 | — | — | US | claimed |
| US-20220127261-A1 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | CERTEGO ABC, LLC | 2022-04-28 | — | — | US | claimed |
| US-20220008398-A1 | GABOXADOL FOR REDUCING RISK OF SUICIDE AND RAPID RELIEF OF DEPRESSION | Certego Therapeutics (US) | 2022-01-13 | — | — | US | claimed |
| WO-2021236876-A2 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | Certego Therapeutics Inc. (US) | 2021-11-25 | — | — | WO | claimed |
| EP-3883566-A1 | GABOXADOL FOR REDUCING RISK OF SUICIDE AND RAPID RELIEF OF DEPRESSION | Certego Therapeutics Inc. (US) | 2021-09-29 | — | — | EP | claimed |
| US-11123332-B2 | Gaboxadol for reducing risk of suicide and rapid relief of depression | Certego Therapeutics Inc. (US) | 2021-09-21 | — | — | US | claimed |
| US-10966965-B2 | — | — | 2021-04-06 | — | — | US | claimed |
| US-20200155522-A1 | GABOXADOL FOR REDUCING RISK OF SUICIDE AND RAPID RELIEF OF DEPRESSION | Certego Therapeutics (US) | 2020-05-21 | — | — | US | claimed |
| CN-109414444-A | Neuroactive steroids, compositions and uses thereof | 萨奇治疗股份有限公司 | 2019-03-01 | — | — | CN | claimed |
| CN-102802635-A | Anaesthetic formulation | GOODCHILD INVEST PTY LTD | 2012-11-28 | — | — | CN | claimed |
| US-8128906-B2 | Stabilized uncoated particles of reversed liquid crystalline phase materials | LYOTROPIC THERAPEUTICS, INC. (US) | 2012-03-06 | — | — | US | claimed |
| CN-102300566-A | Cutaneous application of vasoconstrictors | — | 2011-12-28 | — | — | CN | claimed |
| US-20100303718-A1 | Stabilized Uncoated Particles of Reversed Liquid Crystalline Phase Materials | ANDERSON DAVID | 2010-12-02 | — | — | US | claimed |
| CN-1703199-A | Aggregate with enhanced deformability comprising at least three amphiphiles for improved transport through a semi-permeable barrier and use of non-invasive drugs in vivo, in particular through the skin | IDEA AG (DE) | 2005-11-30 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183238-A1 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | GABRD, GABRA6, GABRA3 | G6PD 2073/4885GABRA1 8/4885GABRB2 14/4885 |
| US-20220127261-A1 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | GABRD, GABRA6, GABRA3 | G6PD 2073/4885GABRA1 8/4885GABRB2 14/4885 |
| US-11597726-B2 | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders | GABRD, GABRA6, GABRA3 | G6PD 2073/4885GABRA1 8/4885GABRB2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.